- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 348539, 11 pages
A Novel Strategy for Inducing the Antitumor Effects of Triterpenoid Compounds: Blocking the Protumoral Functions of Tumor-Associated Macrophages via STAT3 Inhibition
Department of Cell Pathology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan
Received 1 January 2014; Accepted 4 February 2014; Published 11 March 2014
Academic Editor: Masahisa Jinushi
Copyright © 2014 Yukio Fujiwara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. A. Stefater, S. Ren, R. A. Lang, and J. S. Duffield, “Metchnikoff's policemen: macrophages in development, homeostasis and regeneration,” Trends in Molecular Medicine, vol. 17, no. 12, pp. 743–752, 2011.
- J. W. Pollard, “Trophic macrophages in development and disease,” Nature Reviews Immunology, vol. 9, no. 4, pp. 259–270, 2009.
- F. Porcheray, S. Viaud, A.-C. Rimaniol et al., “Macrophage activation switching: an asset for the resolution of inflammation,” Clinical and Experimental Immunology, vol. 142, no. 3, pp. 481–489, 2005.
- S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, pp. 23–35, 2003.
- D. M. Mosser, “The many faces of macrophage activation,” Journal of Leukocyte Biology, vol. 73, no. 2, pp. 209–212, 2003.
- A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati, “The chemokine system in diverse forms of macrophage activation and polarization,” Trends in Immunology, vol. 25, no. 12, pp. 677–686, 2004.
- S. Goerdt and C. E. Orfanos, “Other functions, other genes: alternative activation of antigen-presenting cells,” Immunity, vol. 10, no. 2, pp. 137–142, 1999.
- F. O. Martinez, S. Gordon, M. Locati, and A. Mantovani, “Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression,” Journal of Immunology, vol. 177, no. 10, pp. 7303–7311, 2006.
- A. Mantovani, T. Schioppa, S. K. Biswas, F. Marchesi, P. Allavena, and A. Sica, “Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations,” Tumori, vol. 89, no. 5, pp. 459–468, 2003.
- A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, “Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy,” European Journal of Cancer, vol. 42, no. 6, pp. 717–727, 2006.
- C. E. Lewis and J. W. Pollard, “Distinct role of macrophages in different tumor microenvironments,” Cancer Research, vol. 66, no. 2, pp. 605–612, 2006.
- T. Hagemann, S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis, “Regulation of macrophage function in tumors: the multifaceted role of NF-κB,” Blood, vol. 113, no. 14, pp. 3139–3146, 2009.
- J. A. Joyce and J. W. Pollard, “Microenvironmental regulation of metastasis,” Nature Reviews Cancer, vol. 9, no. 4, pp. 239–252, 2009.
- A. Sica, P. Larghi, A. Mancino et al., “Macrophage polarization in tumour progression,” Seminars in Cancer Biology, vol. 18, no. 5, pp. 349–355, 2008.
- Y. Komohara, M. Jinushi, and M. Takeya, “Clinical significance of macrophage heterogeneity in human malignant tumors,” Cancer Science, vol. 105, pp. 1–8, 2014.
- Y. Komohara, J. Hirahara, T. Horikawa et al., “AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype,” Journal of Histochemistry and Cytochemistry, vol. 54, no. 7, pp. 763–771, 2006.
- Y. Komohara, K. Ohnishi, J. Kuratsu, and M. Takeya, “Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas,” Journal of Pathology, vol. 216, no. 1, pp. 15–24, 2008.
- Y. Komohara, D. Niino, Y. Saito et al., “Clinical significance of CD163+ tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma,” Cancer Science, vol. 104, pp. 945–951, 2013.
- M. A. A. Zaki, N. Wada, J. Ikeda et al., “Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma,” Virchows Archiv, vol. 459, no. 4, pp. 361–366, 2011.
- Y. Komohara, H. Hasita, K. Ohnishi et al., “Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma,” Cancer Science, vol. 102, no. 7, pp. 1424–1431, 2011.
- H. Hasita, Y. Komohara, H. Okabe et al., “Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma,” Cancer Science, vol. 101, no. 8, pp. 1913–1919, 2010.
- B. O. Fabriek, M. M. J. Polfliet, R. P. M. Vloet et al., “The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor,” Blood, vol. 109, no. 12, pp. 5223–5229, 2007.
- L. C. Bover, M. Cardó-Vila, A. Kuniyasu et al., “A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications,” Journal of Immunology, vol. 178, no. 12, pp. 8183–8194, 2007.
- M. Kristiansen, J. H. Graversen, C. Jacobsen et al., “Identification of the haemoglobin scavenger receptor,” Nature, vol. 409, no. 6817, pp. 198–201, 2001.
- J. G. Calvert, D. E. Slade, S. L. Shields et al., “CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses,” Journal of Virology, vol. 81, no. 14, pp. 7371–7379, 2007.
- B. O. Fabriek, R. V. Bruggen, D. M. Deng et al., “The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria,” Blood, vol. 113, no. 4, pp. 887–892, 2009.
- P. Philippidis, J. C. Mason, B. J. Evans et al., “Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery,” Circulation Research, vol. 94, no. 1, pp. 119–126, 2004.
- C. A. Schaer, G. Schoedon, A. Imhof, M. O. Kurrer, and D. J. Schaer, “Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin,” Circulation Research, vol. 99, no. 9, pp. 943–950, 2006.
- Y. Fujiwara, Y. Komohara, T. Ikeda, and M. Takeya, “Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages,” Cancer Science, vol. 102, no. 1, pp. 206–211, 2011.
- H. Yu, M. Kortylewski, and D. Pardoll, “Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment,” Nature Reviews Immunology, vol. 7, no. 1, pp. 41–51, 2007.
- A. Matsukawa, K. Takeda, S. Kudo, T. Maeda, M. Kagayama, and S. Akira, “Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils,” Journal of Immunology, vol. 171, no. 11, pp. 6198–6205, 2003.
- K. Takeda, B. E. Clausen, T. Kaisho et al., “Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of stat3 in macrophages and neutrophils,” Immunity, vol. 10, no. 1, pp. 39–49, 1999.
- A. Sica and V. Bronte, “Altered macrophage differentiation and immune dysfunction in tumor development,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1155–1166, 2007.
- Y. Xu, R. Ge, J. Du et al., “Corosolic acid induces apoptosis through mitochondrial pathway and caspases activation in human cervix adenocarcinoma HeLa cells,” Cancer Letters, vol. 284, no. 2, pp. 229–237, 2009.
- M. S. Lee, C. M. Lee, E. Y. Cha et al., “Activation of AMP-activated protein kinase on human gastric cancer cells by apoptosis induced by corosolic acid isolated from Weigela subsessilis,” Phytotherapy Research, vol. 24, no. 12, pp. 1857–1861, 2010.
- M. S. Lee, E. Y. Cha, P. T. Thuong, J. Y. Kim, M. S. Ahn, and J. Y. Sul, “Down-regulation of human epidermal growth factor receptor 2/neu oncogene by corosolic acid induces cell cycle arrest and apoptosis in NCI-N87 human gastric cancer cells,” Biological and Pharmaceutical Bulletin, vol. 33, no. 6, pp. 931–937, 2010.
- X. Wang, H. Bai, X. Zhang et al., “Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis,” Carcinogenesis, vol. 34, pp. 1323–1330, 2013.
- B. Chakravarti, R. Maurya, J. A. Siddiqui et al., “In vitro anti-breast cancer activity of ethanolic extract of Wrightia tomentosa: role of pro-apoptotic effects of oleanolic acid and urosolic acid,” Journal of Ethnopharmacology, vol. 142, pp. 72–79, 2012.
- M.-H. Shyu, T.-C. Kao, and G.-C. Yen, “Oleanolic acid and ursolic acid induce apoptosis in HuH7 human hepatocellular carcinoma cells through a mitochondrial-dependent pathway and downregulation of XIAP,” Journal of Agricultural and Food Chemistry, vol. 58, no. 10, pp. 6110–6118, 2010.
- N. H. Thoennissen, G. B. Iwanski, N. B. Doan, et al., “Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells,” Cancer Research, vol. 69, pp. 5876–5884, 2009.
- K. V. Gurova, J. E. Hill, C. Guo et al., “Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 48, pp. 17448–17453, 2005.
- Q. Liu, D. Zhao, X. Chen et al., “Determination of corosolic acid, a natural potential anti-diabetes compound, in rat plasma by high-performance liquid chromatography-mass spectrometry and its application to pharmacokinetic and bioavailability studies,” Planta Medica, vol. 77, no. 15, pp. 1707–1711, 2011.
- D. I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte, “Coordinated regulation of myeloid cells by tumours,” Nature Reviews Immunology, vol. 12, no. 4, pp. 253–268, 2012.
- T. Condamine and D. I. Gabrilovich, “Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function,” Trends in Immunology, vol. 32, no. 1, pp. 19–25, 2011.
- J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” Nature Reviews Cancer, vol. 4, no. 1, pp. 71–78, 2004.
- J. S. Wang, T. N. Ren, and T. Xi, “Ursolic acid induces apoptosis by suppressing the expression of FoxM1 in MCF-7 human breast cancer cells,” Medical Oncology, vol. 29, no. 1, pp. 10–15, 2012.
- X. Wang, F. Zhang, L. Yang et al., “Ursolic acid inhibits proliferation and induces apoptosis of cancer cells in vitro and in vivo,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 419343, 8 pages, 2011.
- W. Wang, C. Zhao, D. Jou et al., “Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3,” Anticancer Research, vol. 33, pp. 4279–4284, 2013.
- P. O. Harmand, R. Duval, C. Delage, and A. Simon, “Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells,” International Journal of Cancer, vol. 114, no. 1, pp. 1–11, 2005.
- N. Gao, S. Cheng, A. Budhraja et al., “Ursolic acid induces apoptosis in human leukaemia cells and exhibits anti-leukaemic activity in nude mice through the PKB pathway,” British Journal of Pharmacology, vol. 165, no. 6, pp. 1813–1826, 2012.
- K. Liu, L. Guo, L. Miao et al., “Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells,” Anticancer Drugs, vol. 24, pp. 494–503, 2013.
- J. Li, X. Liang, and X. Yang, “Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways,” Oncology Reports, vol. 28, pp. 501–510, 2012.
- K. Gabrusiewicz, A. Ellert-Miklaszewska, M. Lipko, M. Sielska, M. Frankowska, and B. Kaminska, “Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas,” PLoS ONE, vol. 6, no. 8, Article ID e23902, 2011.
- G. Germano, R. Frapolli, M. Simone et al., “Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells,” Cancer Research, vol. 70, no. 6, pp. 2235–2244, 2010.
- T. L. Rogers and I. Holen, “Tumour macrophages as potential targets of bisphosphonates,” Journal of translational medicine, vol. 9, p. 177, 2011.
- N. Jing and D. J. Tweardy, “Targeting Stat3 in cancer therapy,” Anti-Cancer Drugs, vol. 16, no. 6, pp. 601–607, 2005.
- Y. Fujiwara, Y. Komohara, R. Kudo et al., “Oleanolic acid inhibits macrophage differentiation into the M2 phenotype and glioblastoma cell proliferation by suppressing the activation of STAT3,” Oncology Reports, vol. 26, no. 6, pp. 1533–1537, 2011.
- H. Horlad, Y. Fujiwara, K. Takemura et al., “Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells,” Molecular Nutrition and Food Research, vol. 57, pp. 1046–1054, 2013.